Tirzepatide (Zepbound, Mounjaro): Landscape and Competition

Tirzepatide, Eli Lilly’s once-weekly injection sold as Mounjaro for type 2 diabetes and Zepbound for weight management and sleep apnea, is the main driver of Lilly’s growth: Lilly attributes its third-quarter 2026 revenue increase primarily to Mounjaro and Zepbound, which together brought in about $16 billion. This spotlight summarizes what the labels say as of November 4, 2026, what the key trials showed, and where competitors are pressing.

Mechanism at a glance

Tirzepatide is a dual agonist of the GIP and GLP-1 receptors, injected under the skin once a week. Semaglutide, its main rival, acts on the GLP-1 receptor alone. The Zepbound label carries a boxed warning about thyroid C-cell tumors seen in rats, and it says tirzepatide should not be combined with other tirzepatide products or any GLP-1 receptor agonist. In trials the most common side effects were gastrointestinal and mostly occurred during dose escalation.

Why it matters

The current US labels (DailyMed, revised August 2026) cover four uses. Zepbound is indicated, with diet and activity, to reduce excess body weight and maintain the reduction in adults with obesity, or with overweight plus a weight-related condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity. Mounjaro is indicated for glycemic control in adults and children aged 10 and older with type 2 diabetes, and, since August 2026, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk. We did not find a heart failure indication on either label.

Key trial data, all Lilly-funded:

• SURMOUNT-1 (2,539 adults with obesity, 72 weeks): mean weight change of -15.0%, -19.5% and -20.9% at 5, 10 and 15 mg versus -3.1% on placebo.
• SURMOUNT-OSA (two 52-week trials): apnea-hypopnea index fell by 25.3 and 29.3 events per hour on tirzepatide versus 5.3 and 5.5 on placebo.
• SURPASS-CVOT (13,299 patients with type 2 diabetes and atherosclerotic disease, versus dulaglutide): the primary cardiovascular event occurred in 12.2% versus 13.1% (hazard ratio 0.92, 95.3% CI 0.83 to 1.01). Non-inferiority was met; superiority was not.

On sales, Lilly reported Q3 2026 Mounjaro revenue of $10.7 billion (up 65%) and Zepbound revenue of $5.35 billion (up 49%). Lilly said worldwide volume rose 53% while realized prices fell 15%, and raised 2026 revenue guidance to $91 to $92 billion.

Competitive pressure points

• Semaglutide (Novo Nordisk): the established GLP-1 rival. In SURMOUNT-5, an open-label head-to-head in obesity, weight loss at 72 weeks was 20.2% with tirzepatide versus 13.7% with semaglutide. See our comparison guide and the semaglutide landscape.
• Orforglipron (Lilly’s own pill): Foundayo generated $184 million in Q3 2026 revenue; see our orforglipron spotlight.
• Retatrutide (Lilly): a triple agonist. Lilly reported it beat Ozempic 2 mg in type 2 diabetes in a Phase 3 trial; see our retatrutide spotlight. A head-to-head against tirzepatide in obesity is listed as active, not recruiting.
• CagriSema (Novo Nordisk): in REDEFINE 4 it did not meet its primary non-inferiority endpoint against tirzepatide; see our CagriSema guide.
• Pricing: the 15% fall in realized prices shows that volume, not price, is driving growth. Outside the US, prices fell 29%, which Lilly tied mainly to Mounjaro’s inclusion on China’s national reimbursement list.

What to watch

• Whether Lilly adds further labels. We could not verify the regulatory status of tirzepatide in heart failure with preserved ejection fraction, so none is described here.
• Retatrutide and eloralintide combination programs, which Lilly is positioning against its own tirzepatide.
• Generic semaglutide in Canada, India, China and Brazil, which changes pricing in markets where both drugs compete.
• Peer-reviewed detail on trial subgroups, and how to read registry records; see our ClinicalTrials.gov guide.

Recent developments

Updated November 4, 2026. Items are drawn from company announcements, regulators and trade press; links go to the sources.

• Oct 29, 2026: Lilly reported Q3 revenue of $24.4 billion (up 39%), Mounjaro $10.7 billion, Zepbound $5.35 billion, and raised 2026 revenue guidance to $91 to $92 billion. It also reported that the eloralintide and tirzepatide combination (EloraTZP) beat tirzepatide 15 mg on weight loss and A1C in adults with obesity and type 2 diabetes, with Phase 3 trials to start in Q4 2026. (Lilly Q3 report, SEC)
• Aug 28, 2026: Lilly announced FDA approval of Mounjaro to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk, based on SURPASS-CVOT. (HCPLive; Mounjaro label)
• Dec 2025: SURPASS-CVOT was published in the New England Journal of Medicine. (Europe PMC)
• May 11, 2025: SURMOUNT-5 (tirzepatide versus semaglutide in obesity) was published online in the New England Journal of Medicine. (Europe PMC)

Upcoming catalysts

• Q4 2026: Lilly plans to start Phase 3 trials of eloralintide combined with tirzepatide.
• November 2026: estimated primary completion of the retatrutide versus tirzepatide obesity trial (TRIUMPH-5, NCT06662383). This is a registry date, not a results date.

Bottom line

Tirzepatide has moved from a diabetes launch to a franchise with four labeled uses, and Lilly’s Q3 numbers show volume growth alongside falling realized prices. Its rivals are now measured against it in head-to-head trials, including those from Lilly itself.

Want this kind of analysis for the cardiovascular and metabolic areas you compete in? Request information and we will share sample deliverables.

This article is for informational and competitive-intelligence purposes only and is not medical advice. Approvals, labels and trial results change; verify details against current prescribing information and primary sources.